SCHEDULE 13G/A: BlackRock Discloses 6.7% Passive Stake in Nektar Therapeutics
Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 6.7% beneficial ownership stake in Nektar Therapeutics as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 12,528,006 shares of Nektar Therapeutics common stock.
- This ownership represents 6.7% of Nektar Therapeutics' outstanding common stock.
- BlackRock holds sole voting power over 12,332,547 shares.
- BlackRock holds sole dispositive power over 12,528,006 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Nektar Therapeutics.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Investment Management, LLC, are identified as entities that beneficially own shares, with at least one owning 5% or more of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative operational news for the issuer.
Risks
- The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, indicating a passive investment stance by BlackRock.
Future Outlook
NA
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing is a standard disclosure of institutional ownership and does not provide specific insights into broader industry trends or Nektar Therapeutics' competitive position beyond indicating a significant institutional investor's stake.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, confirming BlackRock's passive investment approach.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney revoked by the new one. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-03-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-04-17 | Date the Schedule 13G Amendment No. 1 was signed by BlackRock, Inc. |
Keywords
BlackRock, Nektar Therapeutics, Schedule 13G, beneficial ownership, common stock, institutional investor, passive investment, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.